Exploring environmental modifiers of LRRK2-associated Parkinson's disease penetrance: An exposomics and metagenomics pilot study on household dust

被引:0
|
作者
Andujar, Begona Talavera [1 ]
Pereira, Sandro L. [1 ]
Busi, Susheel Bhanu [1 ,2 ]
Usnich, Tatiana [3 ]
Borsche, Max [3 ,4 ]
Ertan, Sibel [5 ]
Bauer, Peter [6 ]
Rolfs, Arndt [6 ]
Hezzaz, Soraya [1 ]
Ghelfi, Jenny [1 ]
Brueggemann, Norbert [3 ,4 ]
Antony, Paul [1 ]
Wilmes, Paul [1 ,7 ]
Klein, Christine [3 ]
Gruenewald, Anne [1 ]
Schymanski, Emma L. [1 ]
机构
[1] Univ Luxembourg, Luxembourg Ctr Syst Biomed LCSB, L-4367 Belvaux, Luxembourg
[2] UK Ctr Ecol & Hydrol, Wallingford, Oxon, England
[3] Univ Lubeck, Inst Neurogenet, Lubeck, Germany
[4] Univ Lubeck, Dept Neurol, Lubeck, Germany
[5] Koc Univ, Sch Med, Dept Neurol, Istanbul, Turkiye
[6] CENTOGENE GmbH, Rostock, Germany
[7] Univ Luxembourg, Fac Sci Technol & Med, Dept Life Sci & Med, L-4362 Esch Sur Alzette, Luxembourg
关键词
Indoor environment; Exposomics; Metagenomics; Parkinson's disease; Leucine-rich repeat kinase 2 (LRRK2); Bisphenol S; MASS-SPECTROMETRY; MITOCHONDRIAL DYSFUNCTION; OXIDATIVE STRESS; PIPECOLIC ACID; IN-VITRO; MANAGEMENT; RELEVANCE; FIPRONIL; BACTERIA;
D O I
10.1016/j.envint.2024.109151
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Pathogenic variants in the Leucine-rich repeat kinase 2 (LRRK2) gene are a primary monogenic cause of Parkinson's disease (PD). However, the likelihood of developing PD with inherited LRRK2 pathogenic variants differs (a phenomenon known as "reduced penetrance"), with factors including age and geographic region, highlighting a potential role for lifestyle and environmental factors in disease onset. To investigate this, household dust samples from four different groups of individuals were analyzed using metabolomics/exposomics and metagenomics approaches: PD+/LRRK2+ (PD patients with pathogenic LRRK2 variants; n = 11), PD-/LRRK2+ (individuals with pathogenic LRRK2 variants but without PD diagnosis; n = 8), iPD (PD of unknown cause; n = 11), and a matched, healthy control group (n = 11). The dust was complemented with metabolomics and lipidomics of matched serum samples, where available. A total of 1,003 chemicals and 163 metagenomic operational taxonomic units (mOTUs) were identified in the dust samples, of which ninety chemicals and ten mOTUs were statistically significant (ANOVA p-value < 0.05). Reduced levels of 2-benzothiazolesulfonic acid (BThSO3) were found in the PD-/LRRK2+ group compared to the PD+/LRRK2+ . Among the significant chemicals tentatively identified in dust, two are hazardous chemical replacements: Bisphenol S (BPS), and perfluorobutane sulfonic acid (PFBuS). Furthermore, various lipids were found altered in serum including different lysophosphatidylethanolamines (LPEs), and lysophosphatidylcholines (LPCs), some with higher levels in the PD+/LRRK2+ group compared to the control group. A cellular study on isogenic neurons generated from a PD+/LRRK2+ patient demonstrated that BPS negatively impacts mitochondrial function, which is implicated in PD pathogenesis. This pilot study demonstrates how non-target metabolomics/exposomics analysis of indoor dust samples complemented with metagenomics can prioritize relevant chemicals that may be potential modifiers of LRRK2 penetrance.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Molecular mechanisms defining penetrance of LRRK2-associated Parkinson's disease
    Trinh, Joanne
    Schymanski, Emma L.
    Smajic, Semra
    Kasten, Meike
    Sammler, Esther
    Gruenewald, Anne
    MEDIZINISCHE GENETIK, 2022, 34 (02) : 103 - 116
  • [2] Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
    Healy, Daniel G.
    Falchi, Mario
    O'Sullivan, Sean S.
    Bonifati, Vincenzo
    Durr, Alexandra
    Bressman, Susan
    Brice, Alexis
    Aasly, Jan
    Zabetian, Cyrus P.
    Goldwurm, Stefano
    Ferreira, Joaquim J.
    Tolosa, Eduardo
    Kay, Denise M.
    Klein, Christine
    Williams, David R.
    Marras, Connie
    Lang, Anthony E.
    KWszolek, Zbigniew
    Berciano, Jose
    Schapira, Anthony H. V.
    Lynch, Timothy
    Bhatia, Kailash P.
    Gasser, Thomas
    Lees, Andrew J.
    Wood, Nicholas W.
    LANCET NEUROLOGY, 2008, 7 (07): : 583 - 590
  • [3] Clinical features of LRRK2-associated Parkinson's disease
    Pchelina, S. N.
    Ivanova, O. N.
    Emelyanov, A. K.
    Yakimovskii, A. F.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2011, 111 (12) : 56 - 62
  • [4] CLINICAL FEATURES OF LRRK2-ASSOCIATED PARKINSON'S DISEASE
    Ivanova, O.
    Pchelina, S.
    Yakimovskii, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 556 - 556
  • [5] Motor phenotype of LRRK2-associated Parkinson's disease: a longitudinal study
    Nabli, F.
    Ben Sassi, S.
    Hentati, E.
    Lakhdhar, I.
    Nahdi, H.
    Amouri, R.
    Hentati, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 321 - 321
  • [6] Motor Phenotype of LRRK2-Associated Parkinson's Disease: A Tunisian Longitudinal Study
    Nabli, Fatma
    Ben Sassi, Samia
    Amouri, Rim
    Duda, John E.
    Farrer, Matthew J.
    Hentati, Faycal
    MOVEMENT DISORDERS, 2015, 30 (02) : 253 - 258
  • [7] The function of Golgi apparatus in LRRK2-associated Parkinson's disease
    Wei, Yonghang
    Awan, Maher un Nisa
    Bai, Liping
    Bai, Jie
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2023, 16
  • [8] LIPAD (LRRK2/Luebeck) International Parkinson's Disease Study: Detecting genetic and environmental modifiers of penetrance and disease expression
    Usnich, T.
    Schell, N.
    Vollstedt, E. -J.
    Skrahina, V.
    Bogdanovic, X.
    Koleva-Alazeh, N.
    Csoti, I.
    Foerster, T.
    Heuer, A.
    Brueggemann, N.
    Bauer, P.
    Kasten, M.
    Rolfs, A.
    Klein, C.
    MOVEMENT DISORDERS, 2020, 35 : S214 - S214
  • [9] Microarray expression analysis in idiopathic and LRRK2-associated Parkinson's disease
    Botta-Orfila, Teresa
    Tolosa, Eduard
    Gelpi, Ellen
    Sanchez-Pla, Alex
    Marti, Maria-Jose
    Valldeoriola, Francesc
    Fernandez, Mane
    Carmona, Francesc
    Ezquerra, Mario
    NEUROBIOLOGY OF DISEASE, 2012, 45 (01) : 462 - 468
  • [10] Investigating voice as a biomarker of LRRK2-associated Parkinson's disease (PD)
    Arora, S.
    Visanji, N. P.
    Mestre, T. A.
    Ghate, T.
    Lang, A. E.
    Little, M.
    Marras, C.
    MOVEMENT DISORDERS, 2016, 31 : S215 - S215